Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…Abstract Number: 0967 • ACR Convergence 2023
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
Background/Purpose: Immune checkpoint inhibitors (ICI) increase one-year survival in metastatic non-small cell lung cancer (mNSCLC) from 49% to 69% with chemotherapy-based regimens. Patients with rheumatoid…Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…Abstract Number: 2565 • ACR Convergence 2023
The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021
Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…Abstract Number: 0970 • ACR Convergence 2023
Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change
Background/Purpose: British Columbia's health policy mandated that all new anti-TNF initiations after June 2017 use biosimilars when available, providing the context for a natural experiment.…Abstract Number: 1477 • ACR Convergence 2023
Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Background/Purpose: Herpes zoster (HZ) is characterized by a painful dermatomal rash and is associated with increased healthcare costs and reduced quality of life. Systemic lupus…Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…Abstract Number: 1544 • ACR Convergence 2023
Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and…Abstract Number: 0165 • ACR Convergence 2023
Hypothyroidism Is Associated with Worse Clinical and Utilization Outcomes After Primary Total Knee Arthroplasty
Background/Purpose: Limited information is available regarding how medical comorbidities affect the outcomes of total knee arthroplasty (TKA). The association of medical comorbidities with post-TKA outcomes…Abstract Number: 0999 • ACR Convergence 2023
Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization
Background/Purpose: Over 450,000 primary total hip arthroplasties (THA) are performed each year. One major indication for primary THA is the presence of osteoarthritis (OA). Patient…Abstract Number: 1807 • ACR Convergence 2023
Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty
Background/Purpose: Most data on the effect of comorbidities on primary total hip arthroplasty (THA) outcomes is focused on conditions that directly impact joint health, or…Abstract Number: 0183 • ACR Convergence 2023
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Background/Purpose: Despite greater prevalence of lupus among diverse, racial and ethnic minority populations, marked gaps exist between populations affected by lupus and those enrolled in…Abstract Number: 1027 • ACR Convergence 2023
Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis
Background/Purpose: Access to care varies across health systems. Countries with universal health insurance are thought to have less wealth-based health disparities, but it is unclear…Abstract Number: 1818 • ACR Convergence 2023
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 13
- Next Page »